Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-methyl-6-phenylquinazoline-2,4-diamine is a synthetic small molecule belonging to the quinazoline class of heterocyclic aromatic compounds. It features a quinazoline core substituted with methyl and phenyl groups as well as two amino groups at positions 2 and 4. The compound has been studied primarily in experimental settings and is not approved for clinical use. Its molecular formula is C15H14N4 with an average molecular weight of approximately 250.3 g/mol[1][3][9]. According to DrugBank, it has been identified as an experimental agent with no current approved indications or clinical trial activity[1]. Biotin carboxylase has been listed as a potential target in structural databases, but the pharmacological action remains unknown[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-methyl-6-phenylquinazoline-2,4-diamine.